Pharmacogénétique des anti-inflammatoires non stéroïdiens
作者： V. Rollason , C. Samer , J. A. Desmeules
DOI: 10.1007/S11724-013-0356-6
关键词:
摘要: Les anti-inflammatoires non steroidiens (AINS) sont la classe de medicaments plus frequemment utilisee, que ce soit sur prescription medicale ou « over the counter » (OTC). Leur utilisation est basee une administration empirique avec un monitoring clinique qui permet juger l’efficacite et toxicite. La reponse individuelle peut toutefois etre modulee par des facteurs pharmacocinetiques pharmacodynamiques parmi lesquels certains genetiques. Cette revue resume les principales donnees pharmacogenetiques disponibles expliquant en partie variation interindividuelle d’efficacite toxicite AINS, notamment pour le CYP2C9, uridine diphosphate glucuronosyltransferase cyclooxygenases.
springer.com
sci-hub.se 参考文章(73)
Craig R. Lee, John A. Pieper, Reginald F. Frye, Alan L. Hinderliter, Joyce A. Blaisdell, Joyce A. Goldstein, Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes. European Journal of Clinical Pharmacology. ,vol. 58, pp. 791- 794 ,(2003) , 10.1007/S00228-003-0574-6
Lévesque E, Bélanger A, Hum Dw, Beaulieu M, Characterization and substrate specificity of UGT2B4 (E458): a UDP-glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics. ,vol. 9, pp. 207- 216 ,(1999)
Mia Sandberg, Ümit Yasar, Patrik Strömberg, Jan-Olov Höög, Erik Eliasson, Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase. British Journal of Clinical Pharmacology. ,vol. 54, pp. 423- 429 ,(2002) , 10.1046/J.1365-2125.2002.01660.X
Patricia McGettigan, Lisa F. Lincz, John Attia, Patrick McElduff, Linda Bissett, Roseanne Peel, Barrie Stokes, Stephen Hancock, Kim Henderson, Michael Seldon, David Henry, The risk of coronary thrombosis with cyclo-oxygenase-2 inhibitors does not vary with polymorphisms in two regions of the cyclo-oxygenase-2 gene British Journal of Clinical Pharmacology. ,vol. 72, pp. 707- 714 ,(2011) , 10.1111/J.1365-2125.2011.03957.X
Byron Cryer, George Triadafilopoulos, C Mel Wilcox, Patterns of use and public perception of over-the-counter pain relievers: focus on nonsteroidal antiinflammatory drugs. The Journal of Rheumatology. ,vol. 32, pp. 2218- 2224 ,(2005)
J PERINI, R VIANNAJORGE, A BROGLIATO, G SUAREZKURTZ, Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam Clinical Pharmacology & Therapeutics. ,vol. 78, pp. 362- 369 ,(2005) , 10.1016/J.CLPT.2005.06.014
A Murad, SJ Lewis, G Davey Smith, SM Collin, L Chen, FC Hamdy, DE Neal, J Donovan, RM Martin, None, PTGS2 –899G>C and prostate cancer risk: a population-based nested case–control study (ProtecT) and a systematic review with meta-analysis Prostate Cancer and Prostatic Diseases. ,vol. 12, pp. 296- 300 ,(2009) , 10.1038/PCAN.2009.18
Gary A. Green, Understanding NSAIDs: from aspirin to COX-2. Clinical Cornerstone. ,vol. 3, pp. 50- 59 ,(2001) , 10.1016/S1098-3597(01)90069-9
Craig R. Lee, Frank G. Bottone, Joseph M. Krahn, Leping Li, Harvey W. Mohrenweiser, Molly E. Cook, Robert M. Petrovich, Douglas A. Bell, Thomas E. Eling, Darryl C. Zeldin, Identification and functional characterization of polymorphisms in human cyclooxygenase-1 (PTGS1) Pharmacogenetics and Genomics. ,vol. 17, pp. 145- 160 ,(2007) , 10.1097/01.FPC.0000236340.87540.E3
Yuji Mano, Takashi Usui, Hidetaka Kamimura, Identification of Human UDP-Glucuronosyltransferase Responsible for the Glucuronidation of Niflumic Acid in Human Liver Pharmaceutical Research. ,vol. 23, pp. 1502- 1508 ,(2006) , 10.1007/S11095-006-0250-5